AU2019249249B2 - Methods and compositions for treating skin disease with recombinant microorganisms - Google Patents

Methods and compositions for treating skin disease with recombinant microorganisms Download PDF

Info

Publication number
AU2019249249B2
AU2019249249B2 AU2019249249A AU2019249249A AU2019249249B2 AU 2019249249 B2 AU2019249249 B2 AU 2019249249B2 AU 2019249249 A AU2019249249 A AU 2019249249A AU 2019249249 A AU2019249249 A AU 2019249249A AU 2019249249 B2 AU2019249249 B2 AU 2019249249B2
Authority
AU
Australia
Prior art keywords
filaggrin
coding sequence
skin
polypeptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019249249A
Other languages
English (en)
Other versions
AU2019249249A1 (en
Inventor
Travis Michael Whitfill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azitra Inc
Original Assignee
Azitra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azitra Inc filed Critical Azitra Inc
Publication of AU2019249249A1 publication Critical patent/AU2019249249A1/en
Application granted granted Critical
Publication of AU2019249249B2 publication Critical patent/AU2019249249B2/en
Priority to AU2025204408A priority Critical patent/AU2025204408A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
AU2019249249A 2018-04-05 2019-04-05 Methods and compositions for treating skin disease with recombinant microorganisms Active AU2019249249B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204408A AU2025204408A1 (en) 2018-04-05 2025-06-12 Methods and compositions for treating skin disease with recombinant microorganisms

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862653021P 2018-04-05 2018-04-05
US62/653,021 2018-04-05
PCT/US2019/026045 WO2019195714A1 (en) 2018-04-05 2019-04-05 Methods and compositions for treating skin disease with recombinant microorganisms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204408A Division AU2025204408A1 (en) 2018-04-05 2025-06-12 Methods and compositions for treating skin disease with recombinant microorganisms

Publications (2)

Publication Number Publication Date
AU2019249249A1 AU2019249249A1 (en) 2020-10-22
AU2019249249B2 true AU2019249249B2 (en) 2025-03-13

Family

ID=68101164

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019249249A Active AU2019249249B2 (en) 2018-04-05 2019-04-05 Methods and compositions for treating skin disease with recombinant microorganisms
AU2025204408A Pending AU2025204408A1 (en) 2018-04-05 2025-06-12 Methods and compositions for treating skin disease with recombinant microorganisms

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025204408A Pending AU2025204408A1 (en) 2018-04-05 2025-06-12 Methods and compositions for treating skin disease with recombinant microorganisms

Country Status (7)

Country Link
US (2) US11850267B2 (https=)
JP (2) JP2021528041A (https=)
KR (1) KR20200139760A (https=)
CN (1) CN112236153B (https=)
AU (2) AU2019249249B2 (https=)
CA (1) CA3096081A1 (https=)
WO (1) WO2019195714A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019050898A1 (en) * 2017-09-05 2019-03-14 Azitra Inc METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY SKIN DISEASE
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
FR3144162A1 (fr) * 2022-12-21 2024-06-28 L'oreal Utilisation de souches de Staphylococcus epidermidis produisant des métabolites indoliques pour améliorer la barrière cutanée
CN116874576B (zh) * 2023-06-28 2024-03-12 胡荣洋 一种重组人源化丝聚蛋白及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068946A2 (en) * 2005-12-15 2007-06-21 University Court Of The University Of Dundee Identification of loss-of-function mutations in filaggrin causing ichthyosis vulgaris and predisposing to other diseases
US20130018000A1 (en) * 2009-11-23 2013-01-17 Research Development Foundation Recombinant filaggrin polypeptides for cell importation
WO2015184134A1 (en) * 2014-05-30 2015-12-03 Azitra Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
AU2014203006B2 (en) * 2009-11-23 2016-05-19 Research Development Foundation Recombinant filaggrin polypeptides for cell importation
WO2019050898A1 (en) * 2017-09-05 2019-03-14 Azitra Inc METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY SKIN DISEASE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283287B2 (en) * 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CN104955951A (zh) * 2012-10-16 2015-09-30 麻省理工学院 稳定的非多腺苷酸化rna的产生
ES2939542T3 (es) * 2014-01-31 2023-04-24 Factor Bioscience Inc Métodos y productos para la producción y la administración de ácido nucleico

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068946A2 (en) * 2005-12-15 2007-06-21 University Court Of The University Of Dundee Identification of loss-of-function mutations in filaggrin causing ichthyosis vulgaris and predisposing to other diseases
US20130018000A1 (en) * 2009-11-23 2013-01-17 Research Development Foundation Recombinant filaggrin polypeptides for cell importation
AU2014203006B2 (en) * 2009-11-23 2016-05-19 Research Development Foundation Recombinant filaggrin polypeptides for cell importation
WO2015184134A1 (en) * 2014-05-30 2015-12-03 Azitra Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
WO2019050898A1 (en) * 2017-09-05 2019-03-14 Azitra Inc METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY SKIN DISEASE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THOMAS E. STOUT ET AL: "Recombinant Filaggrin Is Internalized and Processed to Correct Filaggrin Deficiency", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 134, no. 2, (2014), pages 423-429, DOI: 10.1038/jid.2013.284 *

Also Published As

Publication number Publication date
KR20200139760A (ko) 2020-12-14
US20240238349A1 (en) 2024-07-18
CA3096081A1 (en) 2019-10-10
CN112236153A (zh) 2021-01-15
AU2019249249A1 (en) 2020-10-22
AU2025204408A1 (en) 2025-07-10
WO2019195714A8 (en) 2020-07-23
EP3773487A1 (en) 2021-02-17
JP2024063022A (ja) 2024-05-10
JP2021528041A (ja) 2021-10-21
US11850267B2 (en) 2023-12-26
CN112236153B (zh) 2025-04-29
US20210121504A1 (en) 2021-04-29
WO2019195714A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
US12569521B2 (en) Methods and compositions for treating inflammatory skin disease with recombinant microorganisms
US20240238349A1 (en) Methods and compositions for treating skin disease with recombinant microorganisms
US12128129B2 (en) Lactobacillus plantarum for skin care
US20250009818A1 (en) Bacteria strains for topical skin care
US20210070823A1 (en) Methods and compositions for treating atopic dermatitis with recombinant microorganisms

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)